Follow-up care for new cases of polyarthritis in children and young adults
Official title: Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults. Optimization of Clinical Response, Remission, Quality of Life and Analysis of Prognostic Markers
Run by Université Catholique de Louvain · NCT07000916 · Data updated 2026-11-12
This program will try standardized medical follow-up for children and young adults (≤50) with new-onset JIA, RA, psoriatic/seronegative/undifferentiated arthritis, SLE, or diffuse systemic sclerosis who are treatment-naïve or treated ≤3 months to see if more patients reach disease control or remission.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 50 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | September 11, 2013 |
| Main results expected | March 31, 2028 |
| Study ends | March 31, 2028 |
| Registry record updated | June 3, 2025 |
| Trial ID | NCT07000916 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and young adults aged ≤50 with a new diagnosis of JIA, RA, psoriatic/seronegative/undifferentiated arthritis, SLE, or diffuse systemic sclerosis who are treatment‑naïve or have received basic therapy for ≤3 months (except JIA) are ideal candidates.
✕Probably not a fit
Patients treated for more than 3 months, older than 50, or with established long-standing disease are unlikely to benefit from the early standardized follow-up targeted here.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational program will enroll young patients (up to 50 years) newly diagnosed with juvenile idiopathic arthritis, rheumatoid/psoriatic/seronegative/undifferentiated arthritis, systemic lupus erythematosus, or diffuse systemic sclerosis who are treatment‑naïve or treated ≤3 months (except JIA). Participants will be organized into five disease cohorts and undergo standardized clinical monitoring with predefined response and remission criteria based on international definitions. The project seeks to progressively increase capture of new incident cases—targeting 25% initially with a 20% annual increase over 5–10 years—to harmonize care across the participating French‑speaking university centers. Primary outcomes include the proportion of patients achieving good disease control or clinical remission under the standardized follow‑up.
Why it matters
Potential benefit: If successful, this approach could increase the number of young patients who achieve good disease control or clinical remission through earlier, standardized follow-up and care.
How similar studies have gone: Early-treatment and standardized monitoring approaches have improved remission rates in RA and JIA in prior work, though combining multiple pediatric and young adult rheumatic diseases in a single standardized program is less commonly studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria). * Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA. Exclusion Criteria: * Treated for \> 3 months * \> 50 years old
Where it's running
-
UCLouvain
Brussels, Belgium Recruiting
Study contacts
- Study coordinator: Patrick Durez
- Email: patrick.durez@uclouvain.be
- Phone: +32 02 764 53 89
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Creating Health online course for people with rheumatological conditions
This project will test whether an online course about diet and self-care helps adults with rheumatoid arthritis, Sjogren's syndrome, lupus, mixed connective tissue disease, or psoriatic arthritis reduce fatigue and improve quality of life.
-
Educational tool for melanoma patients with autoimmune diseases
This study is testing a new educational tool to help melanoma patients with autoimmune diseases understand their treatment options better and see how easy it is for them to use.
-
Registry and biorepository for rheumatic diseases
This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.
-
Using nivolumab to treat patients with autoimmune disorders and advanced cancer
This study is testing if nivolumab can safely help people with autoimmune disorders who also have advanced cancer by looking at how well it works and what side effects it might cause.
-
Test of HBM7020 in healthy adults and adults with autoimmune diseases
This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.
-
ABBV-519 in adults with SLE or RA: safety and how the drug moves through the body after IV and subcutaneous doses
This early study tests how ABBV-519 behaves in the body and its safety for adults with SLE or RA after single escalating doses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.